Array ( [0] => {{Short description|Medication used to treat cancer}} [1] => {{cs1 config|name-list-style=vanc}} [2] => {{Infobox drug [3] => | Verifiedfields = changed [4] => | verifiedrevid = 460018795 [5] => | image = Carboplatin-skeletal.svg [6] => | alt = [7] => | image2 = Carboplatin-from-xtal-view-1-Mercury-3D-balls.png [8] => | alt2 = [9] => [10] => [11] => | pronounce = {{IPAc-en|ˈ|k|ɑː|ɹ|b|oʊ|ˌ|p|l|æ|t|ə|n}} [12] => | tradename = Paraplatin, others [13] => | Drugs.com = {{drugs.com|monograph|carboplatin}} [14] => | MedlinePlus = a695017 [15] => | routes_of_administration = [[Intravenous]] [16] => | ATC_prefix = L01 [17] => | ATC_suffix = XA02 [18] => | ATC_supplemental = [19] => [20] => | legal_CA = Rx-only [21] => | legal_CA_comment = {{cite web | title=Product monograph brand safety updates | website=[[Health Canada]] | date=7 July 2016 | url=https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database/label-safety-assessment-update/product-monograph-brand-safety-updates.html | access-date=3 April 2024}} [22] => | legal_status = Rx-only [23] => [24] => [25] => | bioavailability = complete [26] => | protein_bound = Very low [27] => | metabolism = [28] => | elimination_half-life = 1.1-2 hours [29] => | excretion = Kidney [30] => [31] => [32] => | CAS_number_Ref = {{cascite|correct|??}} [33] => | CAS_number = 41575-94-4 [34] => | PubChem = 498142 [35] => | DrugBank_Ref = {{drugbankcite|correct|drugbank}} [36] => | DrugBank = DB00958 [37] => | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} [38] => | ChemSpiderID = 8514637 [39] => | UNII_Ref = {{fdacite|correct|FDA}} [40] => | UNII = BG3F62OND5 [41] => | KEGG_Ref = {{keggcite|correct|kegg}} [42] => | KEGG = D01363 [43] => | ChEBI_Ref = {{ebicite|correct|EBI}} [44] => | ChEBI = 31355 [45] => | ChEMBL_Ref = {{ebicite|changed|EBI}} [46] => | ChEMBL = 288376 [47] => | synonyms = [48] => [49] => [50] => | IUPAC_name = ''cis''-diammine(cyclobutane-1,1-dicarboxylate-''O'',''O''')platinum(II) [51] => | C=6 | H=12 | N=2 | O=4 | Pt=1 [52] => | smiles = C1CC2(C1)C(=O)O[Pt-2]([NH3+])([NH3+])OC2=O [53] => | StdInChI_Ref = {{stdinchicite|correct|chemspider}} [54] => | StdInChI = 1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2 [55] => | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} [56] => | StdInChIKey = OLESAACUTLOWQZ-UHFFFAOYSA-L [57] => }} [58] => [59] => [60] => '''Carboplatin''', sold under the brand name '''Paraplatin''' among others, is a [[chemotherapy]] medication used to treat a number of forms of [[cancer]]. This includes [[ovarian cancer]], [[lung cancer]], [[head and neck cancer]], [[brain cancer]], and [[neuroblastoma]]. It is used by [[intravenous|injection into a vein]].{{cite web|title=Carboplatin|url=https://www.drugs.com/monograph/carboplatin.html|publisher=The American Society of Health-System Pharmacists|access-date=8 December 2016|url-status=live|archive-url=https://web.archive.org/web/20161221012052/https://www.drugs.com/monograph/carboplatin.html|archive-date=21 December 2016}} [61] => [62] => [63] => Side effects generally occur. Common side effects include [[cytopenia|low blood cell levels]], nausea, and [[electrolyte problems]].{{cite journal | vauthors = Oun R, Moussa YE, Wheate NJ | title = The side effects of platinum-based chemotherapy drugs: a review for chemists | journal = Dalton Transactions | volume = 47 | issue = 19 | pages = 6645–6653 | date = May 2018 | pmid = 29632935 | doi = 10.1039/c8dt00838h }} Other serious side effects include [[allergic reactions]] and [[mutagenesis]]. It may be [[carcinogenic]], but further research is needed to confirm this. Use during [[pregnancy]] may result in harm to the baby. Carboplatin is in the [[platinum-based antineoplastic]] family of medications and works by interfering with duplication of [[DNA]].{{cite journal | vauthors = Apps MG, Choi EH, Wheate NJ | title = The state-of-play and future of platinum drugs | journal = Endocrine-Related Cancer | volume = 22 | issue = 4 | pages = R219–R233 | date = August 2015 | pmid = 26113607 | doi = 10.1530/ERC-15-0237 | doi-access = free | hdl = 2123/24426 | hdl-access = free }} [64] => [65] => [66] => Carboplatin was developed as a less toxic analogue of [[cisplatin]]. It was patented in 1972 and approved for medical use in 1989.{{cite book| vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery|date=2006|publisher=John Wiley & Sons|isbn=9783527607495|page=513|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA513|language=en|url-status=live|archive-url=https://web.archive.org/web/20161220163817/https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA513|archive-date=2016-12-20}} It is on the 2023 [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].{{cite book |title=The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) |vauthors=((World Health Organization)) |publisher=World Health Organization |year=2023 |location=Geneva |hdl=10665/371090 |id=WHO/MHP/HPS/EML/2023.02 |author-link=World Health Organization |hdl-access=free}} [67] => [68] => ==Medical uses== [69] => Carboplatin is used to treat a number of forms of [[cancer]]. This includes [[ovarian cancer]], [[lung cancer]], [[head and neck cancer]], [[brain cancer]], and [[neuroblastoma]]. It may be used for some types of [[testicular cancer]] but [[cisplatin]] is generally more effective. It has also been used to treat [[triple-negative breast cancer]]. [70] => [71] => ==Side effects== [72] => Relative to [[cisplatin]], the greatest benefit of carboplatin is its reduced side effects, particularly the elimination of [[nephrotoxicity|nephrotoxic]] effects. [[Nausea]] and [[vomiting]] are less severe and more easily controlled.{{Cite book |title=Manual of Hematopoietic Cell Transplantation and Cellular Therapies |vauthors=Gulbis AM, Wallis WD |year=2023 |pages=125–143 |chapter=10 - Preparative Regimens Used in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapies |publisher=Elsevier |doi=10.1016/B978-0-323-79833-4.00010-3|isbn=9780323798334 }} [73] => [74] => The main drawback of carboplatin is its myelosuppressive effect. This causes the [[blood cell]] and [[platelet]] output of bone marrow in the body to decrease quite dramatically, sometimes as low as 10% of its usual production levels. The nadir of this [[myelosuppression]] usually occurs 21–28 days after the first treatment, after which the blood cell and platelet levels in the blood begin to stabilize, often coming close to its pre-carboplatin levels. This decrease in [[white blood cell]]s ([[neutropenia]]) can cause complications, and is sometimes treated with drugs like [[filgrastim]]. The most notable complication of neutropenia is increased probability of infection by opportunistic organisms, which necessitates [[hospital readmission]] and treatment with [[antibiotic]]s. [75] => [76] => ==Mechanism of action== [77] => Carboplatin differs from cisplatin in that it has a [[bidentate]] dicarboxylate (the ligand is cyclobutane dicarboxylate, CBDCA) in place of the two [[chloride]] [[ligand]]s. Both drugs are [[alkylating agent]]s. CBDCA and chloride are the [[leaving group]]s in these respective drugs Carboplatin exhibits slower [[aquation]] (replacement of CBDCA by water) and thus slower DNA binding kinetics, although it forms the same reaction products ''in vitro'' at equivalent doses with cisplatin. Unlike cisplatin, carboplatin may be susceptible to alternative mechanisms. Some results show that cisplatin and carboplatin cause different morphological changes in [[MCF-7]] cell lines while exerting their cytotoxic behaviour.{{cite journal | vauthors = Natarajan G, Malathi R, Holler E | title = Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited | journal = Biochemical Pharmacology | volume = 58 | issue = 10 | pages = 1625–1629 | date = November 1999 | pmid = 10535754 | doi = 10.1016/S0006-2952(99)00250-6 }} The diminished reactivity limits protein-carboplatin complexes, which are excreted. The lower excretion rate of carboplatin means that more is retained in the body, and hence its effects are longer lasting (a retention half-life of 30 hours for carboplatin, compared to 1.5-3.6 hours in the case of cisplatin). [78] => [79] => Like cisplatin, carboplatin binds to and cross-links DNA, interfering with the replication and suppressing growth of the cancer cell.{{cite journal | vauthors = Noll DM, Mason TM, Miller PS | title = Formation and repair of interstrand cross-links in DNA | journal = Chemical Reviews | volume = 106 | issue = 2 | pages = 277–301 | date = February 2006 | pmid = 16464006 | pmc = 2505341 | doi = 10.1021/cr040478b }}{{Cite book |title=Encyclopedia of Respiratory Medicine |vauthors=Edelman MJ, Rupard EJ |year=2006 |pages=332–338 |chapter=TUMORS, MALIGNANT / Chemotherapeutic Agents |publisher=Academic Press |doi=10.1016/B0-12-370879-6/00409-9|isbn=9780123708793 }} [80] => [81] => ==Dose== [82] => Calvert's formula is used to calculate the dose of carboplatin. It considers the creatinine clearance and the desired [[Area under the curve (pharmacokinetics)|area under curve]].{{cite web |url=http://www.mskcc.org/cancer-care/clinical-update/new-guidelines-carboplatin-dosing |title=New Guidelines for Carboplatin Dosing| vauthors = O'Cearbhaill R, Sabbatini PS |date=September 1, 2012|publisher=Memorial Sloan Kettering Cancer Center|access-date=2014-03-27 |url-status=live |archive-url=https://web.archive.org/web/20141031014904/http://www.mskcc.org/cancer-care/clinical-update/new-guidelines-carboplatin-dosing |archive-date=2014-10-31 }} After 24 hours, close to 70% of carboplatin is excreted in the urine unchanged. This means that the dose of carboplatin must be adjusted for any impairment in [[kidney function]].{{cite journal | vauthors = Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E | display-authors = 6 | title = Carboplatin dosage: prospective evaluation of a simple formula based on renal function | journal = Journal of Clinical Oncology | volume = 7 | issue = 11 | pages = 1748–1756 | date = November 1989 | pmid = 2681557 | doi = 10.1200/JCO.1989.7.11.1748 }} [83] => [84] => Calvert formula: \mathrm{Dose}(\mathrm{mg})= \mathrm{AUC} \cdot (\mathrm{GFR} + 25) [85] => [86] => The typical area under the curve (AUC) for carboplatin ranges from 3-7 (mg/ml)*min. [87] => [88] => == Synthesis == [89] => Cisplatin reacts with [[silver nitrate]] and then cyclobutan-1,1-dicarboxylic acid to form carboplatin.{{Cite book |title=Synthesis of Essential Drugs |vauthors=Vardanyan RS, Hruby VJ |year=2006 |pages=389–418 |chapter=30 - Antineoplastics |publisher=Elsevier |doi=10.1016/B978-044452166-8/50030-3|isbn=9780444521668 }} [90] => [[File:Carboplatin synthesis.png|center|thumb|500x131px]] [91] => [92] => ==History== [93] => Carboplatin, a cisplatin analogue, was developed by [[Bristol Myers Squibb]] and the [[Institute of Cancer Research]] in order to reduce the toxicity of cis platin.{{Cite journal |vauthors=Lebwohl D, Canetta R |year=1998 |title=Clinical development of platinum complexes in cancer therapy: an historical perspective and an update |url=https://www.ejcancer.com/action/showPdf?pii=S0959-8049%2898%2900224-X |journal=Eur J Cancer |volume=34 |issue=10 |pages=1522–34 |doi=10.1016/s0959-8049(98)00224-x |pmid=9893623}}{{Cite web |title=Discovering early chemotherapy drugs |url=https://www.icr.ac.uk/about-us/our-achievements/our-scientific-discoveries/we-discovered-chemotherapeutic-agents-which-are-still-in-use-more-than-50-years-later |access-date=2023-10-06 |website=Institute of Cancer Research}} It gained U.S. [[Food and Drug Administration]] (FDA) approval for carboplatin, under the brand name Paraplatin, in March 1989. Starting in October 2004, generic versions of the drug became available. [94] => [95] => ==Research== [96] => Carboplatin has also been used for [[adjuvant therapy]] of stage 1 [[seminoma|seminomatous testicular cancer]]. Research has indicated that it is not less effective than adjuvant [[radiotherapy]] for this treatment, while having fewer side effects.{{cite journal | vauthors = Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP | display-authors = 6 | title = Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial | journal = Lancet | volume = 366 | issue = 9482 | pages = 293–300 | year = 2005 | pmid = 16039331 | doi = 10.1016/S0140-6736(05)66984-X | s2cid = 6001898 | doi-access = free }} This has led to carboplatin based adjuvant therapy being generally preferred over adjuvant radiotherapy in clinical practice.{{cite journal | vauthors = Toner GC | title = Testicular cancer: Optimal management of stage I seminoma in 2015 | journal = Nature Reviews. Urology | volume = 12 | issue = 5 | pages = 249–251 | date = May 2015 | pmid = 25896179 | doi = 10.1038/nrurol.2015.85 | s2cid = 8072355 }} [97] => [98] => Carboplatin combined with [[hexadecyl]] chain and [[polyethylene glycol]] appears to have increased [[liposolubility]] and [[PEGylation]]. This is useful in [[chemotherapy]], specifically non-small cell [[lung cancer]].{{cite journal | vauthors = Lang T, Li N, Zhang J, Li Y, Rong R, Fu Y | title = Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin ''in vivo'' and ''in vitro'' | journal = Drug Delivery | volume = 28 | issue = 1 | pages = 1272–1280 | date = December 2021 | pmid = 34176381 | pmc = 8238065 | doi = 10.1080/10717544.2021.1938754 }} [99] => [100] => == References == [101] => {{Reflist}} [102] => [103] => == Further reading == [104] => * {{cite journal | vauthors = Canetta R, Rozencweig M, Carter SK | title = Carboplatin: the clinical spectrum to date | journal = Cancer Treatment Reviews | volume = 12 Suppl A | issue = Suppl A | pages = 125–136 | date = September 1985 | pmid = 3002623 | doi = 10.1016/0305-7372(85)90027-1 }} [105] => * {{cite journal | vauthors = Yang XL, Wang AH | title = Structural studies of atom-specific anticancer drugs acting on DNA | journal = Pharmacology & Therapeutics | volume = 83 | issue = 3 | pages = 181–215 | date = September 1999 | pmid = 10576292 | doi = 10.1016/S0163-7258(99)00020-0 }} [106] => [107] => {{Chemotherapeutic agents}} [108] => {{Platinum compounds}} [109] => {{Portal bar|Medicine}} [110] => [111] => [[Category:Ammine complexes]] [112] => [[Category:Coordination complexes]] [113] => [[Category:Cyclobutanes]] [114] => [[Category:Organoplatinum compounds]] [115] => [[Category:Platinum(II) compounds]] [116] => [[Category:Platinum-based antineoplastic agents]] [117] => [[Category:Wikipedia medicine articles ready to translate]] [118] => [[Category:World Health Organization essential medicines]] [] => )
good wiki

Carboplatin

Carboplatin, sold under the brand name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma.

More about us

About

Expert Team

Vivamus eget neque lacus. Pellentesque egauris ex.

Award winning agency

Lorem ipsum, dolor sit amet consectetur elitorceat .

10 Year Exp.

Pellen tesque eget, mauris lorem iupsum neque lacus.

You might be interested in

Antibiotic

Antibiotics are a class of drugs that are used to treat and prevent bacterial infections in humans and animals.

Cancer

Cancer is a broad term used to describe a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body.

Chemotherapy

Chemotherapy is a widely used treatment method in the field of oncology, aimed at treating cancer by administering drugs that kill rapidly dividing cells.

Cisplatin

Cisplatin is an anticancer medication that is commonly used in the treatment of various types of cancer, including testicular, ovarian, bladder, and lung cancer.

DNA

DNA, also known as deoxyribonucleic acid, is a molecule that carries the genetic instructions used in the growth, development, functioning, and reproduction of all known living organisms and many viruses.

Filgrastim

Filgrastim, sold under the brand name Neupogen among others, is a medication used to treat low neutrophil count.

Platelet

Platelets, also known as thrombocytes, are tiny blood cells that play a crucial role in preventing excessive bleeding.